

## **S17. Aromatase Inhibitors in Breast Cancer Prevention: The IBIS-II Trial**

J. Cuzick

*Cancer Research UK, Mathematics, Statistics & Epidemiology, London, United Kingdom*

The very promising results of aromatase inhibitors in the adjuvant setting have provided a strong rationale for using these agents in trying to prevent breast cancer. The IBIS II chemoprevention trial has been set up to compare the aromatase inhibitor anastrozole against a placebo in 6,000 high risk post-menopausal women, and against tamoxifen in 4000 post-menopausal women with completely locally excised oestrogen receptor positive

DCIS. Both high efficacy and a low side effect profile are essential for a chemopreventive agent, and this trial is designed to address both of these issues. In particular, a detailed bone substudy in 1000 women is built into the trial, and will evaluate the use of the bisphosphonate risedronate on a randomized basis in osteopenic women. The rationale for, and design of, the trial will be described, and current recruitment status will be reported.